Emerging research directions in CKD treatment should focus on elucidating the blood pressure-independent cardiorenal protective mechanisms of MRAs, as demonstrated in FIDELIO-DKD, including their potential effects on neutrophils and NK cells observed in angiotensin II-induced hypertension models [62, 63]. The gene discussed is AGT; the disease is chronic kidney disease.